Core Points - The FDA has lifted the recommended pause on the use of IXCHIQ for individuals aged 60 and older, following a thorough review by the European Medicines Agency (EMA) [1][2] - IXCHIQ is indicated for the prevention of disease caused by the Chikungunya Virus (CHIKV) in individuals 18 years and older at high risk of exposure [1][2] - The product's prescribing information has been updated to include reports of serious adverse events, particularly among elderly individuals with multiple underlying health conditions [2][4] Company Overview - Valneva SE is a specialty vaccine company focused on developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases [7] - The company has advanced multiple vaccines from early R&D to approvals and currently markets three proprietary travel vaccines [8] - Revenues from the commercial business support the advancement of the vaccine pipeline, including candidates for Lyme disease, Zika virus, and other public health threats [9] Industry Context - Chikungunya virus (CHIKV) is a mosquito-borne disease that has caused significant outbreaks globally, with over 3.7 million cases reported in the Americas between 2013 and 2023 [6] - The World Health Organization (WHO) has identified chikungunya as a major public health problem, with the economic impact expected to grow due to climate change [6]

Core Points - Valneva SE, a specialty vaccine company, announced that all resolutions recommended by the Board of Directors were approved by shareholders at the Annual General Meeting held in Lyon, France [1] - The approved resolutions included the financial statements for 2024, capital increase delegations, and the appointment of Dr. Gerd Zettlmeissl to the Board for a three-year term [2] - Valneva's management confirmed the Company's full-year 2025 financial guidance during the meeting [4] Company Overview - Valneva SE develops, manufactures, and commercializes prophylactic vaccines for infectious diseases, focusing on unmet medical needs [5] - The company has advanced multiple vaccines from early R&D to approvals and currently markets three proprietary travel vaccines [6] - Valneva's commercial business revenues support the advancement of its vaccine pipeline, which includes the only Lyme disease vaccine candidate in advanced clinical development partnered with Pfizer, and other candidates against Shigella, Zika virus, and other public health threats [7] Board and Auditor Information - Dr. Gerd Zettlmeissl, a vaccine expert with over 30 years of experience, was appointed to the Board, while Mr. James Sulat was reappointed for a one-year term [2][3] - The term of Deloitte & Associés as Statutory Auditor was renewed for six years [3]